Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Diabetes

  Free Subscription


Articles published in Diabetes Obes Metab

Retrieve available abstracts of 202 articles:
HTML format
Text format



Single Articles


    June 2017
  1. BAJAJ HS, Ye C, Jain E, Venn K, et al
    Glycemic Improvement with a Fixed-dose combination of DPP-4 inhibitor + metformin in patients with Type 2 Diabetes (GIFT study).
    Diabetes Obes Metab. 2017 Jun 22. doi: 10.1111/dom.13040.
    PubMed     Text format     Abstract available


  2. TSUJIMOTO T, Kajio H, Sugiyama T
    Favourable Changes in Mortality in People with Diabetes - U.S. NHANES 1999-2010.
    Diabetes Obes Metab. 2017 Jun 22. doi: 10.1111/dom.13039.
    PubMed     Text format     Abstract available


  3. GROOP PH, Cooper ME, Perkovic V, Hocher B, et al
    Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.
    Diabetes Obes Metab. 2017 Jun 21. doi: 10.1111/dom.13041.
    PubMed     Text format     Abstract available


  4. KADOWAKI T, Inagaki N, Kondo K, Nishimura K, et al
    Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
    Diabetes Obes Metab. 2017 Jun 13. doi: 10.1111/dom.13038.
    PubMed     Text format     Abstract available


  5. CANOVATCHEL W, Davidson J, Rosenthal N
    Comment on Tang, et al. Sodium-glucose cotransporter 2 inhibitors and risk of adverse renal outcomes among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017; doi: 10.1111/dom.12
    Diabetes Obes Metab. 2017 Jun 9. doi: 10.1111/dom.13035.
    PubMed     Text format     Abstract available


  6. ROUSSEL R, Steg PG, Mohammedi K, Marre M, et al
    Prevention of Cardiovascular Disease by the Reduction of Glycemic Exposure in Type 2 Diabetes: A Perspective on Glucose-Lowering Interventions.
    Diabetes Obes Metab. 2017 Jun 9. doi: 10.1111/dom.13033.
    PubMed     Text format     Abstract available


  7. CONCEICAO J, Dores J, Araujo F, Laires P, et al
    Severe Hypoglycemia Among Patients With Type 2 Diabetes Requiring Emergency Hospital Admission: The HIPOS-ER Study.
    Diabetes Obes Metab. 2017 Jun 5. doi: 10.1111/dom.13030.
    PubMed     Text format     Abstract available


  8. GERSTEIN HC, Colhoun HM, Dagenais GR, Diaz R, et al
    Design and Baseline Characteristics of Participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) Trial of Dulaglutide's Cardiovascular Effects.
    Diabetes Obes Metab. 2017 Jun 1. doi: 10.1111/dom.13028.
    PubMed     Text format     Abstract available


  9. RUSSELL-JONES D, Heller S, Buchs S, Sandberg A, et al
    Projected Long-Term Outcomes in Patients With Type 1 Diabetes Treated With Fast-Acting Insulin Aspart Versus Conventional Insulin Aspart in the Uk Setting.
    Diabetes Obes Metab. 2017 Jun 1. doi: 10.1111/dom.13026.
    PubMed     Text format     Abstract available


    May 2017
  10. BONORA BM, Avogaro A, Fadini GP
    Sodium-Glucose Co-transporter-2 Inhibitors and Diabetic Ketoacidosis. An Updated Review of the Literature.
    Diabetes Obes Metab. 2017 May 18. doi: 10.1111/dom.13012.
    PubMed     Text format     Abstract available


  11. BROWN A, Guess N, Dornhorst A, Taheri S, et al
    Insulin-associated weight gain in obese type 2 diabetes mellitus patients - what can be done?
    Diabetes Obes Metab. 2017 May 16. doi: 10.1111/dom.13009.
    PubMed     Text format     Abstract available


  12. MARCINAK J, Cao C, Lee D, Ye Z, et al
    Fasiglifam for glycemic control in patients with type 2 diabetes: a phase 3, placebo-controlled study.
    Diabetes Obes Metab. 2017 May 11. doi: 10.1111/dom.13004.
    PubMed     Text format     Abstract available


  13. NORTON L, Shannon C, Fourcaudot M, Hu C, et al
    Sodium-glucose (SGLT) and Glucose (GLUT) Transporter Expression in the Kidney of Type 2 Diabetic Subjects.
    Diabetes Obes Metab. 2017 May 6. doi: 10.1111/dom.13003.
    PubMed     Text format     Abstract available


  14. REINSTADLER SJ, Stiermaier T, Eitel C, Metzler B, et al
    Relationship Between Diabetes and Ischemic Injury Among Patients with Revascularized ST-Elevation Myocardial Infarction: Diabetes and Myocardial Damage.
    Diabetes Obes Metab. 2017 May 5. doi: 10.1111/dom.13002.
    PubMed     Text format     Abstract available


  15. DASSAU E, Renard E, Place J, Farret A, et al
    Intraperitoneal Insulin Delivery Provides Superior Glycemic Regulation to Subcutaneous Insulin Delivery in Model Predictive Control-based Fully-automated Artificial Pancreas in Patients with Type 1 Diabetes: A Pilot Study.
    Diabetes Obes Metab. 2017 May 5. doi: 10.1111/dom.12999.
    PubMed     Text format     Abstract available


  16. OWENS DR, Monnier L, Hanefeld M
    A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus.
    Diabetes Obes Metab. 2017 May 4. doi: 10.1111/dom.12998.
    PubMed     Text format     Abstract available


    April 2017
  17. GU S, Wang X, Qiao Q, Gao W, et al
    Cost-Effectiveness of Exenatide twice daily versus Insulin Glargine as add-on Therapy to Oral Anti-diabetic Agents in Type 2 Diabetes in China.
    Diabetes Obes Metab. 2017 Apr 28. doi: 10.1111/dom.12991.
    PubMed     Text format     Abstract available


  18. OWENS D, Bolli G, Charbonnel B, Haak T, et al
    Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/ml added to oral antidiabetes agents in type 2 diabetes.
    Diabetes Obes Metab. 2017 Apr 27. doi: 10.1111/dom.12966.
    PubMed     Text format     Abstract available


  19. TONNEIJCK L, Muskiet MHA, Smits MM, Hoekstra T, et al
    Postprandial renal haemodynamic effect of lixisenatide versus once-daily insulin glulisine in type 2 diabetes patients on insulin-glargine: an 8-week, randomised, open-label trial.
    Diabetes Obes Metab. 2017 Apr 27. doi: 10.1111/dom.12985.
    PubMed     Text format     Abstract available


  20. GANTZ I, Okamoto T, Ito Y, Okuyama K, et al
    A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly DPP-4 inhibitor, in Japanese patients with type 2 diabetes.
    Diabetes Obes Metab. 2017 Apr 27. doi: 10.1111/dom.12988.
    PubMed     Text format     Abstract available


  21. HANEFELD M, Arteaga JM, Leiter LA, Marchesini G, et al
    Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment.
    Diabetes Obes Metab. 2017 Apr 27. doi: 10.1111/dom.12986.
    PubMed     Text format     Abstract available


  22. PARK J, Park SW, Yoon KH, Kim SR, et al
    Efficacy and Safety of Evogliptin Monotherapy in Patients with Type 2 Diabetes and Moderately Elevated HbA1c by Diet and Exercise.
    Diabetes Obes Metab. 2017 Apr 27. doi: 10.1111/dom.12987.
    PubMed     Text format     Abstract available


  23. DAVIES MJ, Leiter LA, Guerci B, Grunberger G, et al
    Impact of baseline HbA1c, diabetes duration and BMI on clinical outcomes in the LixiLan-O trial testing iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine and lixisenatide monocomponents.
    Diabetes Obes Metab. 2017 Apr 22. doi: 10.1111/dom.12980.
    PubMed     Text format     Abstract available


  24. ENGEL SS, Suryawanshi S, Stevens SR, Josse RG, et al
    Safety of Sitagliptin in Patients with Type 2 Diabetes and Chronic Kidney Disease: Outcomes from TECOS.
    Diabetes Obes Metab. 2017 Apr 22. doi: 10.1111/dom.12983.
    PubMed     Text format     Abstract available


  25. FADINI GP, Saragoni S, Russo P, Degli Esposti L, et al
    Intraclass differences in the risk of hospitalisazion for heart failure among type 2 diabetic patients initiating a dipeptydil peptidase-4 inhibitor or a sulphonylurea. Results from the OsMed Health-DB registry.
    Diabetes Obes Metab. 2017 Apr 21. doi: 10.1111/dom.12979.
    PubMed     Text format     Abstract available


  26. OWENS DR, Monnier L, Barnett AH
    Future challenges and therapeutic opportunities in type 2 diabetes: changing the paradigm of current therapy.
    Diabetes Obes Metab. 2017 Apr 21. doi: 10.1111/dom.12977.
    PubMed     Text format     Abstract available


  27. CERIELLO A, De Cosmo S, Rossi MC, Lucisano G, et al
    Variability in HbA1c, blood pressure, lipid parameters and serum uric acid and risk of development of chronic kidney disease in type 2 diabetes.
    Diabetes Obes Metab. 2017 Apr 21. doi: 10.1111/dom.12976.
    PubMed     Text format     Abstract available


  28. GUMMESSON A, Nyman E, Knutsson M, Karpefors M, et al
    Effect of Weight Reduction on Hemoglobin A1c in weight loss trials of Type 2 Diabetes Patients.
    Diabetes Obes Metab. 2017 Apr 18. doi: 10.1111/dom.12971.
    PubMed     Text format     Abstract available


  29. SOLINI A, Rossi C, Mazzanti CM, Proietti A, et al
    SGLT2 and SGLT1 renal expression in patients with type 2 diabetes.
    Diabetes Obes Metab. 2017 Apr 17. doi: 10.1111/dom.12970.
    PubMed     Text format     Abstract available


  30. CUSI K, Sanyal AJ, Zhang S, Hartman ML, et al
    Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes.
    Diabetes Obes Metab. 2017 Apr 17. doi: 10.1111/dom.12973.
    PubMed     Text format     Abstract available


  31. BIESTER T, Aschemeier B, Fath M, Frey M, et al
    Effects of Dapagliflozin on Insulin-requirement, Glucose Excretion, and ss- Hydroxybutyrate levels are not related to Baseline HbA1c in Youth with Type 1 Diabetes.
    Diabetes Obes Metab. 2017 Apr 17. doi: 10.1111/dom.12975.
    PubMed     Text format     Abstract available


  32. MEIER JJ, Schenker N, Kahle M, Schliess F, et al
    Impact of insulin glargine and lixisenatide on beta cell function in patients with type 2 diabetes mellitus: a randomized open-label study.
    Diabetes Obes Metab. 2017 Apr 13. doi: 10.1111/dom.12968.
    PubMed     Text format     Abstract available


  33. ZIMMERMAN RS, Hobbs TM, Wells BJ, Kong SX, et al
    Association of Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Use and Rates of Acute Myocardial Infarction, Stroke, and Overall Mortality in Patients with Type 2 Diabetes Mellitus in a Large Integrated Health System.
    Diabetes Obes Metab. 2017 Apr 13. doi: 10.1111/dom.12969.
    PubMed     Text format     Abstract available


  34. ZGHEBI SS, Steinke DT, Carr MJ, Rutter MK, et al
    Examining Trends in Type 2 Diabetes Incidence, Prevalence and Mortality in the UK between 2004 and 2014.
    Diabetes Obes Metab. 2017 Apr 7. doi: 10.1111/dom.12964.
    PubMed     Text format     Abstract available


  35. CHILTON R, Tikkanen I, Hehnke U, Woerle HJ, et al
    Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension.
    Diabetes Obes Metab. 2017 Apr 6. doi: 10.1111/dom.12962.
    PubMed     Text format     Abstract available


  36. WYSHAM C, Bonadonna RC, Aroda VR, Puig-Domingo M, et al
    Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLa
    Diabetes Obes Metab. 2017 Apr 6. doi: 10.1111/dom.12961.
    PubMed     Text format     Abstract available


  37. METZGER M, Castaneda J, Reznik Y, Giorgino F, et al
    Factors associated with improved glycemic control following continuous subcutaneous insulin infusion therapy in patients with type 2 diabetes uncontrolled with bolus-basal insulin regimens: an analysis from the OpT2mise randomized trial.
    Diabetes Obes Metab. 2017 Apr 4. doi: 10.1111/dom.12960.
    PubMed     Text format     Abstract available


    March 2017
  38. GUZMAN CB, Zhang XM, Liu R, Regev A, et al
    Treatment with LY2409021, a Glucagon Receptor Antagonist, Increases Liver Fat in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Mar 31. doi: 10.1111/dom.12958.
    PubMed     Text format     Abstract available


  39. RUAN Y, Thabit H, Leelarathna L, Hartnell S, et al
    Faster insulin action is associated with improved glycemic outcomes during closed-loop insulin delivery and sensor-augmented pump therapy in adults with type 1 diabetes.
    Diabetes Obes Metab. 2017 Mar 30. doi: 10.1111/dom.12956.
    PubMed     Text format     Abstract available


  40. TERAUCHI Y, Tamura M, Senda M, Gunji R, et al
    Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16 week randomized, double-blind, placebo-controlled multicentre trial.
    Diabetes Obes Metab. 2017 Mar 30. doi: 10.1111/dom.12957.
    PubMed     Text format     Abstract available


  41. LUNDKVIST P, Pereira MJ, Katsogiannos P, Sjostrom CD, et al
    Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: sustained reductions in bodyweight, glycaemia, and blood pressure over 1 year.
    Diabetes Obes Metab. 2017 Mar 27. doi: 10.1111/dom.12954.
    PubMed     Text format     Abstract available


  42. RODBARD HW, Tripathy D, Vidrio Velazquez M, Demissie M, et al
    Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: a randomised, 18-week, open-label, phase 3 trial (onset 3).
    Diabetes Obes Metab. 2017 Mar 27. doi: 10.1111/dom.12955.
    PubMed     Text format     Abstract available


  43. RANJAN A, Schmidt S, Damm-Frydenberg C, Holst J, et al
    Short-term Effects of Low Carbohydrate Diet on Glycaemic Parameters and Cardiovascular Risk Markers in Patients with Type 1 Diabetes - A Randomised Open-label Cross-over Trial.
    Diabetes Obes Metab. 2017 Mar 27. doi: 10.1111/dom.12953.
    PubMed     Text format     Abstract available


  44. YAMADA Y, Senda M, Naito Y, Tamura M, et al
    Reduction of postprandial glucose by lixisenatide versus sitagliptin in Japanese patients with type 2 diabetes on background insulin glargine: a randomised phase 4 study.
    Diabetes Obes Metab. 2017 Mar 26. doi: 10.1111/dom.12945.
    PubMed     Text format     Abstract available


  45. WILLIAMS R, de Vries F, Kothny W, Serban C, et al
    Cardiovascular safety of vildagliptin in patients with type 2 diabetes: a European multi-database, non-interventional post-authorization safety study.
    Diabetes Obes Metab. 2017 Mar 24. doi: 10.1111/dom.12951.
    PubMed     Text format     Abstract available


  46. KULKARNI M, Foraker RE, McNeill AM, Girman C, et al
    Evaluation of the Modified FINDRISC Diabetes Score to Identify Individuals at High Risk for Diabetes among Middle-aged White and Black ARIC Study Participants.
    Diabetes Obes Metab. 2017 Mar 21. doi: 10.1111/dom.12949.
    PubMed     Text format     Abstract available


  47. STAELS F, Moyson C, Mathieu C
    Metformin as add-on to intensive insulin therapy in type 1 diabetes mellitus.
    Diabetes Obes Metab. 2017 Mar 20. doi: 10.1111/dom.12948.
    PubMed     Text format     Abstract available


  48. GARG M, Ghanim H, Kuhadiya ND, Green K, et al
    Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes.
    Diabetes Obes Metab. 2017 Mar 17. doi: 10.1111/dom.12944.
    PubMed     Text format     Abstract available


  49. DU J, Liang L, Fang H, Xu F, et al
    Efficacy and Safety of Saxagliptin Compared with Acarbose in Chinese Patients with Type 2 Diabetes Mellitus Uncontrolled on Metformin Monotherapy: Results of a Phase IV Open-Label Randomized Controlled Study (The SMART Study).
    Diabetes Obes Metab. 2017 Mar 14. doi: 10.1111/dom.12942.
    PubMed     Text format     Abstract available


  50. VAN RAALTE DH, Verchere CB
    Improving glycemic control in type 2 diabetes: stimulate insulin secretion or provide beta-cell rest?
    Diabetes Obes Metab. 2017 Mar 14. doi: 10.1111/dom.12935.
    PubMed     Text format     Abstract available


  51. HEISE T, Norskov M, Nosek L, Kaplan K, et al
    Insulin degludec: lower day-to-day and within-day variability in pharmacodynamic response compared to insulin glargine U300 in type 1 diabetes.
    Diabetes Obes Metab. 2017 Mar 14. doi: 10.1111/dom.12938.
    PubMed     Text format     Abstract available


  52. SALASTEKAR N, Desai T, Hauser T, Schaefer EJ, et al
    Salsalate Improves Glycemia in Overweight Persons With Diabetes Risk Factors of Stable Statin-Treated Cardiovascular Disease: a 30-month Randomized Placebo-Controlled Trial.
    Diabetes Obes Metab. 2017 Mar 14. doi: 10.1111/dom.12940.
    PubMed     Text format     Abstract available


  53. POZZILLI P, Norwood P, Jodar E, Davies MJ, et al
    A placebo-controlled, randomised trial of the addition of once weekly GLP-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
    Diabetes Obes Metab. 2017 Mar 14. doi: 10.1111/dom.12937.
    PubMed     Text format     Abstract available


  54. BOULANGER M, Al-Shahi Salman R, Kerssens J, Wild SH, et al
    Association between diabetes mellitus and incidence and case-fatality after stroke due to intracerebral haemorrhage: a retrospective population-based cohort study.
    Diabetes Obes Metab. 2017 Mar 9. doi: 10.1111/dom.12934.
    PubMed     Text format     Abstract available


  55. TERAUCHI Y, Yamada Y, Ishida H, Ohsugi M, et al
    The efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients aged 60 years or older with type 2 diabetes mellitus (START-J trial).
    Diabetes Obes Metab. 2017 Mar 9. doi: 10.1111/dom.12933.
    PubMed     Text format     Abstract available


  56. FLORY J, Stempniewicz N, Keating S, Gerhard T, et al
    Comparative Adherence to Diabetes Drugs: An Analysis of Electronic Health Records and Claims Data.
    Diabetes Obes Metab. 2017 Mar 7. doi: 10.1111/dom.12931.
    PubMed     Text format     Abstract available


  57. UMPIERREZ G, O'Neal D, DiGenio A, Goldenberg R, et al
    Lixisenatide reduces glycemic variability in insulin-treated patients with type 2 diabetes.
    Diabetes Obes Metab. 2017 Mar 3. doi: 10.1111/dom.12930.
    PubMed     Text format     Abstract available


  58. MAURICIO D, Meneghini L, Seufert J, Liao L, et al
    Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA.
    Diabetes Obes Metab. 2017 Mar 2. doi: 10.1111/dom.12927.
    PubMed     Text format     Abstract available


  59. STADLER M, Bollow E, Fritsch M, Kerner W, et al
    Prevalence of Elevated Liver Enzymes in Adults with Type 1 Diabetes: a Multicenter Analysis of the German/Austrian DPV Database.
    Diabetes Obes Metab. 2017 Mar 2. doi: 10.1111/dom.12929.
    PubMed     Text format     Abstract available


    February 2017
  60. DE BOER SA, Heerspink HJ, Juarez Orozco LE, van Roon AM, et al
    Effect of linagliptin on pulse wave velocity in early type 2 diabetes (RELEASE): a randomized, double-blind, controlled 26-week trial.
    Diabetes Obes Metab. 2017 Feb 28. doi: 10.1111/dom.12925.
    PubMed     Text format     Abstract available


  61. TANG H, Li D, Zhang J, Li Y, et al
    Sodium-glucose cotransporter 2 inhibitors and risk of adverse renal outcomes among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2017 Feb 27. doi: 10.1111/dom.12917.
    PubMed     Text format     Abstract available


  62. PENG XV, Marcinak JF, Raanan MG, Cao C, et al
    Combining the GPR40 agonist fasiglifam with sitagliptin improves glycemic control in patients with type 2 diabetes with or without metformin: a randomized, 12-week trial.
    Diabetes Obes Metab. 2017 Feb 27. doi: 10.1111/dom.12921.
    PubMed     Text format     Abstract available


  63. LIAN JX, McGhee SM, So C, Chau J, et al
    Five-year cost-effectiveness of Patient Empowerment Programme (PEP) for type 2 diabetes mellitus in primary care.
    Diabetes Obes Metab. 2017 Feb 23. doi: 10.1111/dom.12919.
    PubMed     Text format     Abstract available


  64. ALBER A, Bronden A, Knop FK
    Short-acting GLP-1 receptor agonists as add-on to insulin therapy in type 1 diabetes - a review.
    Diabetes Obes Metab. 2017 Feb 17. doi: 10.1111/dom.12911.
    PubMed     Text format     Abstract available


  65. PAUL SK, Owusu Adjah ES, Samanta M, Patel K, et al
    Comparison of body mass index at diagnosis of diabetes in a multiethnic population: a case-control study with matched non-diabetic controls.
    Diabetes Obes Metab. 2017 Feb 17. doi: 10.1111/dom.12915.
    PubMed     Text format     Abstract available


  66. LEITER LA, Zamorano JL, Bujas-Bobanovic M, Louie MJ, et al
    Lipid-Lowering Efficacy and Safety of Alirocumab in Patients with or without Diabetes: A Sub-Analysis of ODYSSEY COMBO II.
    Diabetes Obes Metab. 2017 Feb 16. doi: 10.1111/dom.12909.
    PubMed     Text format     Abstract available


  67. ABERER F, Hajnsek M, Rumpler M, Zenz S, et al
    Evaluation of Subcutaneous Glucose Monitoring Systems under Routine Environmental Conditions in Patients with Type 1 Diabetes.
    Diabetes Obes Metab. 2017 Feb 16. doi: 10.1111/dom.12907.
    PubMed     Text format     Abstract available


  68. GADDE KM, Vetter ML, Iqbal N, Hardy E, et al
    Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: the DURATION-NEO-2 randomized clinical study.
    Diabetes Obes Metab. 2017 Feb 16. doi: 10.1111/dom.12908.
    PubMed     Text format     Abstract available


  69. BERGMARK BA, Cannon CP, White WB, Jarolim P, et al
    Baseline Adiponectin Concentration and Clinical Outcomes among Patients with Diabetes and Recent Acute Coronary Syndrome in the EXAMINE Trial.
    Diabetes Obes Metab. 2017 Feb 14. doi: 10.1111/dom.12905.
    PubMed     Text format     Abstract available


  70. KAZDA CM, Frias J, Foga I, Cui X, et al
    Treatment with the Glucagon Receptor Antagonist LY2409021 Increases Ambulatory Blood Pressure in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Feb 13. doi: 10.1111/dom.12904.
    PubMed     Text format     Abstract available


  71. SUCHER S, Markova M, Hornemann S, Pivovarova O, et al
    A comparison of the effects of diets high in animal or plant protein on metabolic and cardiovascular markers in type 2 diabetes - a randomized clinical trial.
    Diabetes Obes Metab. 2017 Feb 9. doi: 10.1111/dom.12901.
    PubMed     Text format     Abstract available


  72. ALATORRE C, Fernandez Lando L, Yu M, Brown K, et al
    Treatment Patterns in Patients with Type 2 Diabetes Mellitus Treated with GLP-1 Receptor Agonists: Higher Adherence and Persistence with Dulaglutide Compared to Exenatide QW and Liraglutide.
    Diabetes Obes Metab. 2017 Feb 9. doi: 10.1111/dom.12902.
    PubMed     Text format     Abstract available


  73. KRAMER CK, Zinman B, Choi H, Connelly PW, et al
    Chronic liraglutide therapy induces an enhanced endogenous glucagon-like peptide-1 secretory response in early type 2 diabetes.
    Diabetes Obes Metab. 2017 Feb 9. doi: 10.1111/dom.12858.
    PubMed     Text format     Abstract available


  74. KADOWAKI T, Inagaki N, Kondo K, Nishimura K, et al
    Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: results of a 24-week, randomised, double-blind, placebo-controlled trial.
    Diabetes Obes Metab. 2017 Feb 8. doi: 10.1111/dom.12898.
    PubMed     Text format     Abstract available


    January 2017
  75. RATHMANN W, Strassburger K, Bongaerts B, Bobrov P, et al
    Impact of Insulin Sensitivity, Beta-cell Function and Glycemic Control on Initiation of Second-Line Glucose-Lowering Treatment in Newly Diagnosed Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Jan 27. doi: 10.1111/dom.12894.
    PubMed     Text format     Abstract available


  76. GRAY SG, McGuire T, Cohen N, Little PJ, et al
    The emerging role of Metformin in Gestational Diabetes Mellitus.
    Diabetes Obes Metab. 2017 Jan 27. doi: 10.1111/dom.12893.
    PubMed     Text format     Abstract available


  77. ANHOLM C, Kumarathurai P, Pedersen LR, Nielsen OW, et al
    Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes.
    Diabetes Obes Metab. 2017 Jan 26. doi: 10.1111/dom.12891.
    PubMed     Text format     Abstract available


  78. HUNT B, Vega-Hernandez G, Valentine WJ, Kragh N, et al
    Evaluation of the long-term cost-effectiveness of liraglutide versus lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.
    Diabetes Obes Metab. 2017 Jan 26. doi: 10.1111/dom.12890.
    PubMed     Text format     Abstract available


  79. HARRIS SB, Kocsis G, Prager R, Ridge T, et al
    Safety and Efficacy of IDegLira Titrated Once Weekly versus Twice Weekly in Patients with Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: DUAL VI Randomized Clinical Trial.
    Diabetes Obes Metab. 2017 Jan 26. doi: 10.1111/dom.12892.
    PubMed     Text format     Abstract available


  80. NYSTROM T, Bodegard J, Nathanson D, Thuresson M, et al
    Novel oral glucose-lowering drugs compared to insulin are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycemia in type 2 diabetes patients.
    Diabetes Obes Metab. 2017 Jan 24. doi: 10.1111/dom.12889.
    PubMed     Text format     Abstract available


  81. TERRA SG, Focht K, Davies M, Frias J, et al
    A Phase 3, Efficacy and Safety Study of Ertugliflozin Monotherapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise Alone.
    Diabetes Obes Metab. 2017 Jan 24. doi: 10.1111/dom.12888.
    PubMed     Text format     Abstract available


  82. STORGAARD H, Cold F, Gluud LL, Vilsboll T, et al
    Glucagon-Like Peptide-1 Agonists and Risk of Acute Pancreatitis in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Jan 20. doi: 10.1111/dom.12885.
    PubMed     Text format     Abstract available


  83. JI L, Zhang P, Zhu D, Li X, et al
    Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: Real-life use of basal insulin in China.
    Diabetes Obes Metab. 2017 Jan 20. doi: 10.1111/dom.12886.
    PubMed     Text format     Abstract available


  84. VON SCHOLTEN BJ, Persson F, Rosenlund S, Eugen-Olsen J, et al
    Liraglutide effects on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomised, placebo-controlled, double-blind, cross-over trial.
    Diabetes Obes Metab. 2017 Jan 20. doi: 10.1111/dom.12884.
    PubMed     Text format     Abstract available


  85. HENRY RR, Dandona P, Pettus J, Mudaliar S, et al
    Dapagliflozin in Patients with Type 1 Diabetes: A post-hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting beta-hydroxybutyrate levels from a Phase IIa pilot study.
    Diabetes Obes Metab. 2017 Jan 18. doi: 10.1111/dom.12882.
    PubMed     Text format     Abstract available


  86. RIZZO M, Rizvi AA, Sesti G
    Cardiovascular Effects of GLP-1 Receptor Agonist Therapies in Patients with Type-1 Diabetes.
    Diabetes Obes Metab. 2017 Jan 18. doi: 10.1111/dom.12883.
    PubMed     Text format    


  87. HAIDAR A, Messier V, Legault L, Ladouceur M, et al
    Outpatient 60-hour day-and-night glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or sensor-augmented pump therapy in adults with type 1 diabetes: an open-label, randomised, crossover, controlled trial.
    Diabetes Obes Metab. 2017 Jan 17. doi: 10.1111/dom.12880.
    PubMed     Text format     Abstract available


  88. KIRK RK, Pyke C, von Herrath MG, Hasselby JP, et al
    Immunohistochemical Assessment of Glucagon-like Peptide 1 Receptor (GLP-1R) Expression in the Pancreas of Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Jan 17. doi: 10.1111/dom.12879.
    PubMed     Text format     Abstract available


  89. TSUJIMOTO T, Sugiyama T, Kajio H
    Effects of beta-blockers on all-cause mortality in patients with type 2 diabetes and coronary heart disease.
    Diabetes Obes Metab. 2017 Jan 17. doi: 10.1111/dom.12878.
    PubMed     Text format     Abstract available


  90. GOLDENBERG R, Gantz I, Andryuk PJ, O'Neill EA, et al
    Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled
    Diabetes Obes Metab. 2017 Jan 17. doi: 10.1111/dom.12832.
    PubMed     Text format     Abstract available


  91. DESAI M, Yavin Y, Balis D, Sun D, et al
    Renal Safety of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Patients With Type 2 Diabetes Mellitus.
    Diabetes Obes Metab. 2017 Jan 12. doi: 10.1111/dom.12876.
    PubMed     Text format     Abstract available


  92. JI L, Li L, Kuang J, Yang T, et al
    Efficacy and safety of fixed-dose combination therapy alogliptin plus metformin in Asian patients with type 2 diabetes: a phase 3 trial.
    Diabetes Obes Metab. 2017 Jan 11. doi: 10.1111/dom.12875.
    PubMed     Text format     Abstract available


  93. DASGUPTA K, Rosenberg E, Joseph L, Cooke AB, et al
    Physician Step prescription and Monitoring to improve ARTERial health (SMARTER): a randomized controlled trial in type 2 diabetes and hypertension.
    Diabetes Obes Metab. 2017 Jan 11. doi: 10.1111/dom.12874.
    PubMed     Text format     Abstract available


  94. HAASE M, Kahle M, Janert M, Meier JJ, et al
    Basal rate tests (24 h fasts) performed in type-1 diabetic subjects with either absolute fasting or snacks containing negligible carbohydrate amounts result in similar glucose profiles - a randomized controlled prospective trial.
    Diabetes Obes Metab. 2017 Jan 6. doi: 10.1111/dom.12868.
    PubMed     Text format     Abstract available


  95. PARK YJ, Warnock GL, Ao Z, Safikhan N, et al
    Dual Role of IL-1beta in Islet Amyloid Formation and its beta-Cell Toxicity: Implications in Type 2 Diabetes and Islet Transplantation.
    Diabetes Obes Metab. 2017 Jan 6. doi: 10.1111/dom.12873.
    PubMed     Text format     Abstract available


  96. HELLER SR, Bergenstal RM, White WB, Kupfer S, et al
    Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndromes: the EXAMINE trial.
    Diabetes Obes Metab. 2017 Jan 6. doi: 10.1111/dom.12871.
    PubMed     Text format     Abstract available


  97. PARK SE, Lee BW, Kim JH, Lee WJ, et al
    Effect of gemigliptin on glycemic variability in patients with type 2 diabetes.
    Diabetes Obes Metab. 2017 Jan 6. doi: 10.1111/dom.12869.
    PubMed     Text format     Abstract available


  98. HONG SM, Park CY, Hwang DM, Han KA, et al
    Efficacy and Safety of Adding Evogliptin versus Sitagliptin In Metformin-Treated Patients With Type 2 Diabetes: A 24-week Randomised, Controlled Trial With Open Label Extension.
    Diabetes Obes Metab. 2017 Jan 6. doi: 10.1111/dom.12870.
    PubMed     Text format     Abstract available


    December 2016
  99. AHN CH, Han KA, Yu JM, Nam JY, et al
    Efficacy and Safety of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Combination Treatment of Metformin and Sulfonylurea: a 24-week, multicenter, randomized, double-blind, place
    Diabetes Obes Metab. 2016 Dec 27. doi: 10.1111/dom.12866.
    PubMed     Text format     Abstract available


  100. GORDON J, McEwan P, Evans M, Puelles J, et al
    Managing glycaemia in older people with type 2 diabetes: a retrospective, primary care based cohort study, with economic assessment of patient outcomes.
    Diabetes Obes Metab. 2016 Dec 27. doi: 10.1111/dom.12867.
    PubMed     Text format     Abstract available


  101. MCEWAN P, Bennett H, Qin L, Bergenheim K, et al
    An alternative approach to modelling HbA1c trajectories in patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2016 Dec 27. doi: 10.1111/dom.12865.
    PubMed     Text format     Abstract available


  102. YOON SA, Han BG, Kim SG, Han SY, et al
    Efficacy, Safety, and Albuminuria-Reducing Effect of Gemigliptin in Korean Type 2 Diabetes Patients with Moderate to Severe Renal Impairment: A 12-Week, Double-blind Randomized Study (the GUARD Study).
    Diabetes Obes Metab. 2016 Dec 25. doi: 10.1111/dom.12863.
    PubMed     Text format     Abstract available


  103. PENA MJ, de Zeeuw D, Andress D, Brennan JJ, et al
    The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy.
    Diabetes Obes Metab. 2016 Dec 25. doi: 10.1111/dom.12864.
    PubMed     Text format     Abstract available


  104. FORST T, Falk A, Andersen G, Fischer A, et al
    Effects of sequentially adding empagliflozin and linagliptin on alpha and beta cell function in type 2 diabetic patients on previous metformin treatment - An exploratory mechanistic study.
    Diabetes Obes Metab. 2016 Dec 23. doi: 10.1111/dom.12838.
    PubMed     Text format     Abstract available


  105. MOBINI R, Tremaroli V, Stahlman M, Karlsson F, et al
    Metabolic effects of Lactobacillus reuteri DSM 17938 in Patients with Type 2 Diabetes: A Randomized Controlled Trial.
    Diabetes Obes Metab. 2016 Dec 23. doi: 10.1111/dom.12861.
    PubMed     Text format     Abstract available


  106. KHENSIER K, Kashyap S
    Canagliflozin versus placebo for post-bariatric patients with persistent type II diabetes; a randomized controlled trial (CARAT).
    Diabetes Obes Metab. 2016 Dec 20. doi: 10.1111/dom.12860.
    PubMed     Text format     Abstract available


  107. YABE D, Iwasaki M, Kuwata H, Haraguchi T, et al
    SGLT2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: a randomized, open-label, 3-arm parallel comparative exploratory study.
    Diabetes Obes Metab. 2016 Dec 19. doi: 10.1111/dom.12848.
    PubMed     Text format     Abstract available


  108. KAPITZA C, Nowotny I, Lehmann A, Bergmann K, et al
    Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog(R) in subjects with type 1 diabetes.
    Diabetes Obes Metab. 2016 Dec 17. doi: 10.1111/dom.12856.
    PubMed     Text format     Abstract available


  109. ARAKI E, Onishi Y, Asano M, Kim H, et al
    Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: DAISY trial.
    Diabetes Obes Metab. 2016 Dec 17. doi: 10.1111/dom.12853.
    PubMed     Text format     Abstract available


  110. NAIK S, Belfort-DeAguiar R, Sejling AS, Szepietowska B, et al
    Evaluation of the Counter-regulatory Responses to Hypoglycemia in Patients with Type 1 Diabetes during Opiate Receptor Blockade with Naltrexone.
    Diabetes Obes Metab. 2016 Dec 17. doi: 10.1111/dom.12855.
    PubMed     Text format     Abstract available


  111. NIMRI R, Bratina N, Kordonouri O, Avbelj Stefanija M, et al
    MD-Logic Overnight Type 1 Diabetes Control in Home Settings: Multicenter, Multinational, Single blind, Randomized Trial.
    Diabetes Obes Metab. 2016 Dec 16. doi: 10.1111/dom.12852.
    PubMed     Text format     Abstract available


  112. HTIKE ZZ, Zaccardi F, Papamargaritis D, Webb DR, et al
    Efficacy and Safety of Glucagon-like peptide-1 receptor agonists in type 2 diabetes Systematic review and mixed-treatment comparison analysis.
    Diabetes Obes Metab. 2016 Dec 15. doi: 10.1111/dom.12849.
    PubMed     Text format     Abstract available


  113. DEJGAARD TF, Johansen NB, Frandsen CS, Asmar A, et al
    Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes.
    Diabetes Obes Metab. 2016 Dec 9. doi: 10.1111/dom.12841.
    PubMed     Text format     Abstract available


  114. HOME P
    Comment on Abd El Aziz et al, A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients, Diabetes Obesity Metab 2016; on line ahead of pub
    Diabetes Obes Metab. 2016 Dec 9. doi: 10.1111/dom.12842.
    PubMed     Text format    


  115. PETRIE JR, Chaturvedi N, Ford I, Hramiak I, et al
    Metformin in adults with type 1 diabetes: design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): an international multicentre trial.
    Diabetes Obes Metab. 2016 Dec 9. doi: 10.1111/dom.12840.
    PubMed     Text format     Abstract available


    November 2016
  116. KAKU K, Sumino S, Katou M, Nishiyama Y, et al
    A randomized, double-blind, phase III study to evaluate efficacy and safety of once-daily treatment of alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes.
    Diabetes Obes Metab. 2016 Nov 28. doi: 10.1111/dom.12837.
    PubMed     Text format     Abstract available


  117. PORKSEN N, Linnebjerg H, Garhyan P, Lam EC, et al
    Novel Hepato-Preferential Basal Insulin Peglispro (BIL) Does Not Differentially Affect Insulin Sensitivity Compared with Insulin Glargine in Patients with Type 1 and Type 2 Diabetes.
    Diabetes Obes Metab. 2016 Nov 26. doi: 10.1111/dom.12834.
    PubMed     Text format     Abstract available


  118. FRANDSEN CS, Dejgaard TF, Andersen HU, Holst JJ, et al
    Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: a randomised, placebo-controlled, double-blind, parallel-group study.
    Diabetes Obes Metab. 2016 Nov 21. doi: 10.1111/dom.12830.
    PubMed     Text format     Abstract available


  119. AHN CH, Kim EK, Min SH, Oh TJ, et al
    Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Lipid Metabolism and Endotoxemia after a High-Fat Meal in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2016 Nov 21. doi: 10.1111/dom.12831.
    PubMed     Text format     Abstract available


  120. MOKHLESI B, Grimaldi D, Beccuti G, Van Cauter E, et al
    Effect of One Week of CPAP Treatment of Obstructive Sleep Apnoea on 24-h Profiles of Glucose, Insulin and Counter-regulatory Hormones in Type 2 Diabetes.
    Diabetes Obes Metab. 2016 Nov 17. doi: 10.1111/dom.12823.
    PubMed     Text format     Abstract available


  121. WEI W, Buysman E, Grabner M, Xie L, et al
    A Real-world Study of Treatment Patterns and Outcomes in US Managed-Care Patients With Type 2 Diabetes Initiating Injectable Therapies.
    Diabetes Obes Metab. 2016 Nov 17. doi: 10.1111/dom.12828.
    PubMed     Text format     Abstract available


  122. PREISS D, Dawed A, Welsh P, Heggie A, et al
    The sustained influence of metformin therapy on circulating GLP-1 levels in individuals with and without type 2 diabetes.
    Diabetes Obes Metab. 2016 Nov 13. doi: 10.1111/dom.12826.
    PubMed     Text format     Abstract available


  123. LI D, Wang T, Shen S, Fang Z, et al
    Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose cotransporter 2 inhibitors: a meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2016 Nov 12. doi: 10.1111/dom.12825.
    PubMed     Text format     Abstract available


  124. GHOLAP NN, Achana FA, Davies MJ, Ray KK, et al
    Long-term mortality following acute myocardial infarction among those with and without diabetes: A systematic review and meta-analysis of studies in the post reperfusion era.
    Diabetes Obes Metab. 2016 Nov 12. doi: 10.1111/dom.12827.
    PubMed     Text format     Abstract available


  125. RAYNER CK, Jones KL, Wu T, Horowitz M, et al
    Gut feelings about diabetes and GLP-1 receptor agonists - lessons to be learnt from studies in functional gastrointestinal disorders.
    Diabetes Obes Metab. 2016 Nov 9. doi: 10.1111/dom.12822.
    PubMed     Text format    


  126. VAN MUNSTER SN, van der Graaf Y, de Valk HW, Visseren FL, et al
    Effect modification in the relation between HbA1c and cardiovascular disease and mortality in patients with type 2 diabetes.
    Diabetes Obes Metab. 2016 Nov 2. doi: 10.1111/dom.12820.
    PubMed     Text format     Abstract available


  127. LAUGIER-ROBIOLLE S, Verges B, Le Bras M, Gand E, et al
    Glycemic control impacts the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes.
    Diabetes Obes Metab. 2016 Nov 2. doi: 10.1111/dom.12819.
    PubMed     Text format     Abstract available


  128. YABE D, Eto T, Shiramoto M, Irie S, et al
    Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycemia in Japanese subjects with type 2 diabetes: a randomized, open-label, 2 arm parallel comparative, exploratory trial.
    Diabetes Obes Metab. 2016 Nov 1. doi: 10.1111/dom.12817.
    PubMed     Text format     Abstract available


  129. MITCHELL PL, Nachbar R, Lachance D, St-Pierre P, et al
    Treatment with a novel agent combining docosahexaenoate and metformin increases protectin DX and IL-6 production in skeletal muscle and reduces insulin resistance in obese diabetic db/db mice.
    Diabetes Obes Metab. 2016 Nov 1. doi: 10.1111/dom.12818.
    PubMed     Text format     Abstract available


    October 2016
  130. BLONDE L, Chava P, Dex T, Lin J, et al
    Predictors of type 2 diabetes patients' outcomes in the lixisenatide GetGoal clinical trials.
    Diabetes Obes Metab. 2016 Oct 21. doi: 10.1111/dom.12815.
    PubMed     Text format     Abstract available


  131. TUTTLE KR, Dwight McKinney T, Davidson JA, Anglin G, et al
    The Effects of Once Weekly Dulaglutide on Kidney Function in Patients with Type 2 Diabetes in Phase 2 and 3 Clinical Trials.
    Diabetes Obes Metab. 2016 Oct 21. doi: 10.1111/dom.12816.
    PubMed     Text format     Abstract available


  132. BROGLIO F, Mannucci E, Napoli R, Nicolucci A, et al
    Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: a meta-analysis from the GetGoal program.
    Diabetes Obes Metab. 2016 Oct 20. doi: 10.1111/dom.12810.
    PubMed     Text format     Abstract available


  133. TINAHONES FJ, Gallwitz B, Nordaby M, Gotz S, et al
    Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: two 24-week randomized, double-blind, double-dummy, parallel-group trials.
    Diabetes Obes Metab. 2016 Oct 20. doi: 10.1111/dom.12814.
    PubMed     Text format     Abstract available


  134. WU T, Xie C, Wu H, Jones KL, et al
    Metformin reduces the rate of small intestinal glucose absorption in type 2 diabetes.
    Diabetes Obes Metab. 2016 Oct 20. doi: 10.1111/dom.12812.
    PubMed     Text format     Abstract available


  135. MADJD A, Taylor MA, Delavari A, Malekzadeh R, et al
    Beneficial effects of replacing diet beverages with water on type 2 diabetic obese women following a hypo-energetic diet: A randomized, 24-week clinical trial.
    Diabetes Obes Metab. 2016 Oct 16. doi: 10.1111/dom.12793.
    PubMed     Text format     Abstract available


  136. ABD EL AZIZ MS, Kahle M, Meier JJ, Nauck MA, et al
    A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients.
    Diabetes Obes Metab. 2016 Oct 7. doi: 10.1111/dom.12804.
    PubMed     Text format     Abstract available


  137. SINGH S, Wright EE Jr, Kwan AY, Thompson JC, et al
    Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2016 Oct 7. doi: 10.1111/dom.12805.
    PubMed     Text format     Abstract available


  138. NAUCK MA, Kahle M, Baranov O, Deacon CF, et al
    A randomized controlled trial of adding the DPP-4 inhibitor sitagliptin to ongoing therapy with liraglutide (GLP-1 receptor agonist): Increases in intact GLP-1 and GIP, but no change in insulin, glucagon or plasma glucose following a mixed meal in pat
    Diabetes Obes Metab. 2016 Oct 6. doi: 10.1111/dom.12802.
    PubMed     Text format     Abstract available


  139. HEISE T, Zijlstra E, Nosek L, Rikte T, et al
    Pharmacological properties of faster-acting insulin aspart versus insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: a randomised, double-blind, crossover trial.
    Diabetes Obes Metab. 2016 Oct 6. doi: 10.1111/dom.12803.
    PubMed     Text format     Abstract available


  140. ROHDE U, Federspiel CA, Vilmann P, Langholz E, et al
    The Impact of EndoBarrier Gastrointestinal Liner in Obese Patients with Normal Glucose Tolerance and Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2016 Oct 3. doi: 10.1111/dom.12800.
    PubMed     Text format     Abstract available


  141. CUSI K, Sanyal AJ, Zhang S, Hoogwerf BJ, et al
    Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes.
    Diabetes Obes Metab. 2016;18 Suppl 2:50-58.
    PubMed     Text format     Abstract available


  142. MUDALIAR S, Henry RR, Ciaraldi TP, Armstrong DA, et al
    Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.
    Diabetes Obes Metab. 2016;18 Suppl 2:17-24.
    PubMed     Text format     Abstract available


  143. GRUNBERGER G, Chen L, Rodriguez A, Tinahones FJ, et al
    A randomized clinical trial of basal insulin peglispro vs NPH in insulin-naive patients with type 2 diabetes: the IMAGINE 6 trial.
    Diabetes Obes Metab. 2016;18 Suppl 2:34-42.
    PubMed     Text format     Abstract available


    September 2016
  144. CHOWDHURY TA, Srirathan D, Abraham G, Oei EL, et al
    COULD METFORMIN BE USED IN PATIENTS WITH DIABETES AND ADVANCED CHRONIC KIDNEY DISEASE?
    Diabetes Obes Metab. 2016 Sep 30. doi: 10.1111/dom.12799.
    PubMed     Text format     Abstract available


  145. MOREIRA-LUCAS TS, Duncan AM, Rabasa-Lhoret R, Vieth R, et al
    Effect of vitamin D supplementation on oral glucose tolerance in individuals with low vitamin D status and increased risk for developing type 2 diabetes (EVIDENCE): a double-blind, randomized, placebo-controlled clinical trial.
    Diabetes Obes Metab. 2016 Sep 26. doi: 10.1111/dom.12794.
    PubMed     Text format     Abstract available


  146. MENSBERG P, Nyby S, Jorgensen PG, Storgaard H, et al
    Near-normalisation of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes.
    Diabetes Obes Metab. 2016 Sep 26. doi: 10.1111/dom.12797.
    PubMed     Text format     Abstract available


  147. LIM S, Han KA, Yu JM, Chamnan P, et al
    Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: a double-blind randomized controlled trial (INICOM study).
    Diabetes Obes Metab. 2016 Sep 13. doi: 10.1111/dom.12787.
    PubMed     Text format     Abstract available


  148. JOSSE RG, Majumdar SR, Zheng Y, Adler A, et al
    Sitagliptin and Risk of Fractures in Type 2 Diabetes: Results from the TECOS Trial.
    Diabetes Obes Metab. 2016 Sep 8. doi: 10.1111/dom.12786.
    PubMed     Text format     Abstract available


  149. TANG H, Cui W, Li D, Wang T, et al
    Sodium-glucose cotransporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2016 Sep 6. doi: 10.1111/dom.12785.
    PubMed     Text format     Abstract available


  150. BRAMLAGE P, Lanzinger S, Rathmann W, Gillessen A, et al
    Dyslipidaemia and its treatment in patients with type 2 diabetes - a joint analysis of the German DIVE and DPV registries.
    Diabetes Obes Metab. 2016 Sep 4. doi: 10.1111/dom.12783.
    PubMed     Text format     Abstract available


  151. VIEIRA A, Courtney M, Druelle N, Avolio F, et al
    beta-Cell replacement as a treatment for type 1 diabetes: an overview of possible cell sources and current axes of research.
    Diabetes Obes Metab. 2016;18 Suppl 1:137-43.
    PubMed     Text format     Abstract available


  152. REMEDI MS, Emfinger C
    Pancreatic beta-cell identity in diabetes.
    Diabetes Obes Metab. 2016;18 Suppl 1:110-6.
    PubMed     Text format     Abstract available


  153. BRERETON MF, Rohm M, Ashcroft FM
    beta-Cell dysfunction in diabetes: a crisis of identity?
    Diabetes Obes Metab. 2016;18 Suppl 1:102-9.
    PubMed     Text format     Abstract available


    August 2016
  154. JEFFERY N, Harries LW
    Beta cell differentiation status in type 2 diabetes.
    Diabetes Obes Metab. 2016 Aug 23. doi: 10.1111/dom.12778.
    PubMed     Text format     Abstract available


  155. CARLSON N, Hommel K, Olesen JB, Gerds TA, et al
    Metformin-associated risk of acute dialysis in patients with type 2 diabetes: A nationwide cohort study.
    Diabetes Obes Metab. 2016 Aug 18. doi: 10.1111/dom.12764.
    PubMed     Text format     Abstract available


  156. FRIAS JP, Nakhle S, Ruggles JA, Zhuplatov S, et al
    Exenatide once weekly improved 24-hour glucose control and reduced glycemic variability in metformin-treated patients with type 2 diabetes: a randomized, placebo-controlled trial.
    Diabetes Obes Metab. 2016 Aug 16. doi: 10.1111/dom.12763.
    PubMed     Text format     Abstract available


  157. TAKAHARA M, Shiraiwa T, Katakami N, Matsuoka TA, et al
    Preference in time of insulin injection in type 2 diabetic patients treated with once-daily long-acting insulin analog.
    Diabetes Obes Metab. 2016 Aug 9. doi: 10.1111/dom.12762.
    PubMed     Text format    


  158. PAUL SK, Shaw J, Montvida O, Klein K, et al
    Weight gain in insulin treated patients by BMI categories at treatment initiation: New evidence from real-world data in patients with type 2 diabetes.
    Diabetes Obes Metab. 2016 Aug 9. doi: 10.1111/dom.12761.
    PubMed     Text format     Abstract available


  159. VAJDA EG, Logan D, Lasseter K, Armas D, et al
    Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2016 Aug 8. doi: 10.1111/dom.12752.
    PubMed     Text format     Abstract available


  160. BAIN SC, Feher M, Russell-Jones D, Khunti K, et al
    Management of type 2 diabetes: the current situation and key opportunities to improve care in the UK.
    Diabetes Obes Metab. 2016 Aug 5. doi: 10.1111/dom.12760.
    PubMed     Text format     Abstract available


  161. INAGAKI N, Araki E, Oura T, Matsui A, et al
    The combination of dulaglutide and biguanide reduced body weight in Japanese patients with type 2 diabetes.
    Diabetes Obes Metab. 2016 Aug 3. doi: 10.1111/dom.12758.
    PubMed     Text format     Abstract available


  162. LINNEBJERG H, Lam EC, Zhang X, Seger ME, et al
    Duration of Action of Two Insulin Glargine Products, LY2963016 Insulin Glargine and Lantus(R) Insulin Glargine, in Subjects with Type 1 Diabetes Mellitus.
    Diabetes Obes Metab. 2016 Aug 3. doi: 10.1111/dom.12759.
    PubMed     Text format     Abstract available


  163. JI LN, Pan CY, Lu JM, Li H, et al
    Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION).
    Diabetes Obes Metab. 2016;18:775-82.
    PubMed     Text format     Abstract available


    July 2016
  164. VELLECCO V, Mitidieri E, Gargiulo A, Brancaleone V, et al
    Vascular effects of Linagliptin in Non Obese Diabetic (NOD) mice are glucose-independent and involve positive modulation of Endothelial Nitric Oxide Synthase (eNOS)/caveolin-1 (CAV-1) pathway.
    Diabetes Obes Metab. 2016 Jul 27. doi: 10.1111/dom.12750.
    PubMed     Text format     Abstract available


  165. SMITS MM, Tonneijck L, Muskiet MH, Hoekstra T, et al
    Biliary effects of liraglutide and sitagliptin, a 12-week randomised placebo-controlled trial in type 2 diabetes patients.
    Diabetes Obes Metab. 2016 Jul 23. doi: 10.1111/dom.12748.
    PubMed     Text format     Abstract available


  166. ISHIHARA H, Yamaguchi S, Nakao I, Okitsu A, et al
    Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): A multi-centre, randomized, placebo-controlled, double-blind study.
    Diabetes Obes Metab. 2016 Jul 20. doi: 10.1111/dom.12745.
    PubMed     Text format     Abstract available


  167. TANG HL, Li DD, Zhang JJ, Hsu YH, et al
    Lack of Evidence for a Harmful Effect of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors on Fracture Risk among Type 2 Diabetes Patients: A Network and Cumulative Meta-Analysis of Randomized Controlled Trials.
    Diabetes Obes Metab. 2016 Jul 13. doi: 10.1111/dom.12742.
    PubMed     Text format     Abstract available


  168. GARG S, Selam JL, Bhargava A, Schloot N, et al
    Similar HbA1c Reduction and Hypoglycaemia with Variable- Vs Fixed-Time Dosing of Basal Insulin Peglispro (BIL) in Type 1 Diabetes: IMAGINE 7 Study.
    Diabetes Obes Metab. 2016 Jul 9. doi: 10.1111/dom.12740.
    PubMed     Text format     Abstract available


  169. GARG S, Dreyer M, Jinnouchi H, Mou J, et al
    A Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine, in Combination with Prandial insulin Lispro, in Patients with Type 1 Diabetes: IMAGINE 1.
    Diabetes Obes Metab. 2016 Jul 8. doi: 10.1111/dom.12738.
    PubMed     Text format     Abstract available


  170. MATHIEU C, Herrera Mamolejo M, Gonzalez Gonzalez JG, Hansen L, et al
    Efficacy and Safety of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin Over 52 Weeks in Patients With Type 2 Diabetes.
    Diabetes Obes Metab. 2016 Jul 7. doi: 10.1111/dom.12737.
    PubMed     Text format     Abstract available


  171. BAILEY TS, Takacs R, Tinahones FJ, Rao PV, et al
    Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial.
    Diabetes Obes Metab. 2016 Jul 6. doi: 10.1111/dom.12736.
    PubMed     Text format     Abstract available


  172. SALSALI A, Kim G, Woerle HJ, Broedl UC, et al
    Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials.
    Diabetes Obes Metab. 2016 Jul 4. doi: 10.1111/dom.12734.
    PubMed     Text format     Abstract available


  173. AZAR ST, Echtay A, Wan Bebakar WM, Al Araj S, et al
    Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomised trial.
    Diabetes Obes Metab. 2016 Jul 4. doi: 10.1111/dom.12733.
    PubMed     Text format     Abstract available


  174. PARKINSON J, Tang W, Johansson CC, Boulton DW, et al
    Comparison of the exposure-response relationship of dapagliflozin in adult and paediatric patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2016;18:685-92.
    PubMed     Text format     Abstract available


  175. TIRUCHERAI GS, LaCreta F, Ismat FA, Tang W, et al
    Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2016;18:678-84.
    PubMed     Text format     Abstract available


    June 2016
  176. O'HARTE FP, Ng MT, Lynch AM, Conlon JM, et al
    Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice.
    Diabetes Obes Metab. 2016 Jun 30. doi: 10.1111/dom.12713.
    PubMed     Text format     Abstract available


  177. DAVIES MJ, Russell-Jones D, Selam JL, Bailey TS, et al
    Basal insulin peglispro vs insulin glargine in insulin-naive type 2 diabetes: IMAGINE 2 randomized trial.
    Diabetes Obes Metab. 2016 Jun 28. doi: 10.1111/dom.12712.
    PubMed     Text format     Abstract available


  178. VAN DER SANDE NG, Dorresteijn JA, Visseren FL, Dwyer JP, et al
    Individualized prediction of the effect of angiotensin receptor inhibition on renal and cardiovascular outcomes in patients with diabetic nephropathy.
    Diabetes Obes Metab. 2016 Jun 23. doi: 10.1111/dom.12708.
    PubMed     Text format     Abstract available


  179. DAVIS TM, Badshah I, Chubb SA, Davis WA, et al
    Dose-response relationship between statin therapy and glycaemia in community-based patients with type 2 diabetes: The Fremantle Diabetes Study.
    Diabetes Obes Metab. 2016 Jun 23. doi: 10.1111/dom.12710.
    PubMed     Text format     Abstract available


  180. EKSTROM N, Svensson AM, Miftaraj M, Franzen S, et al
    Cardiovascular Safety of Glucose-Lowering Agents as Add-on Medication to Metformin Treatment in Type 2 Diabetes:Report from the Swedish National Diabetes Register (NDR).
    Diabetes Obes Metab. 2016 Jun 10. doi: 10.1111/dom.12704.
    PubMed     Text format     Abstract available


  181. JENDLE J, Testa MA, Martin S, Jiang H, et al
    Continuous Glucose Monitoring in Type 2 Diabetes Patients Treated with GLP-1 Receptor Agonist Dulaglutide in Combination with Prandial Insulin Lispro - An AWARD-4 Substudy.
    Diabetes Obes Metab. 2016 Jun 9. doi: 10.1111/dom.12705.
    PubMed     Text format     Abstract available


  182. WYSHAM C, Guerci B, D'Alessio D, Jia N, et al
    Baseline Factors Associated with Glycaemic Response to Treatment with Once Weekly Dulaglutide in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2016 Jun 6. doi: 10.1111/dom.12702.
    PubMed     Text format     Abstract available


  183. MAGNUSSEN LV, Glintborg D, Hermann P, Hougaard DM, et al
    Effect of testosterone on insulin sensitivity, oxidative metabolism, and body-composition in aging men with type 2 diabetes on metformin monotherapy.
    Diabetes Obes Metab. 2016 Jun 6. doi: 10.1111/dom.12701.
    PubMed     Text format     Abstract available


  184. YOON KH, Nishimura R, Lee J, Crowe S, et al
    Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four Phase III trials.
    Diabetes Obes Metab. 2016 Jun 6. doi: 10.1111/dom.12699.
    PubMed     Text format     Abstract available


  185. BERGENSTAL RM, Lunt H, Franek E, Travert F, et al
    A Randomized, Double-Blind Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine, in Combination with Prandial Insulin Lispro, in Patients with Type 1 Diabetes: IMAGINE 3.
    Diabetes Obes Metab. 2016 Jun 6. doi: 10.1111/dom.12698.
    PubMed     Text format     Abstract available


    May 2016
  186. BLEVINS T, Pieber TR, Vega GC, Zhang S, et al
    Randomized, Double-Blind Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine, in Combination With Prandial Insulin Lispro, in Patients with Type 2 Diabetes: IMAGINE 4.
    Diabetes Obes Metab. 2016 May 28. doi: 10.1111/dom.12696.
    PubMed     Text format     Abstract available


  187. GERARDS MC, de Maar J, Steenbruggen TG, Hoekstra JB, et al
    Add-on treatment with intermediate-acting insulin versus sliding scale insulin for patients with type 2 diabetes or insulin resistance during cyclic glucocorticoid-containing antineoplastic chemotherapy - a randomized cross-over study.
    Diabetes Obes Metab. 2016 May 18. doi: 10.1111/dom.12694.
    PubMed     Text format     Abstract available


  188. APOVIAN C, Palmer K, Fain R, Perdomo C, et al
    Effects of Lorcaserin on Fat and Lean Mass Loss in Obese and Overweight Patients Without and With Type 2 Diabetes Mellitus: the BLOSSOM and BLOOM-DM Studies.
    Diabetes Obes Metab. 2016 May 13. doi: 10.1111/dom.12690.
    PubMed     Text format     Abstract available


  189. KAKU K, Enya K, Nakaya R, Ohira T, et al
    Long-term safety and efficacy of fasiglifam (TAK-875), a GPR40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study.
    Diabetes Obes Metab. 2016 May 13. doi: 10.1111/dom.12693.
    PubMed     Text format     Abstract available


  190. MORROW LA, Hompesch M, Jacober SJ, Choi SL, et al
    Glucodynamics of Long-Acting Basal Insulin Peglispro (BIL) Compared With Insulin Glargine at Steady State in Subjects with Type 1 Diabetes: substudy of a randomized crossover trial.
    Diabetes Obes Metab. 2016 May 12. doi: 10.1111/dom.12691.
    PubMed     Text format     Abstract available


  191. KHUNTI K, Alsifri S, Aronson R, Berkovic MC, et al
    Rates and predictors of hypoglycaemia in 27,585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study.
    Diabetes Obes Metab. 2016 May 10. doi: 10.1111/dom.12689.
    PubMed     Text format     Abstract available


  192. BOUSTANI MA, Pittman Iv I, Yu M, Thieu VT, et al
    Comparable efficacy and safety of once weekly dulaglutide in patients with type 2 diabetes >/=65 and <65 years of age.
    Diabetes Obes Metab. 2016 May 10. doi: 10.1111/dom.12687.
    PubMed     Text format     Abstract available


  193. PARRINELLO CM, Matsushita K, Woodward M, Wagenknecht LE, et al
    Risk prediction of major complications in persons with diabetes: The Atherosclerosis Risk in Communities Study.
    Diabetes Obes Metab. 2016 May 10. doi: 10.1111/dom.12686.
    PubMed     Text format     Abstract available


  194. SKOW MA, Bergmann NC, Knop FK
    Diabetes and obesity treatment based on dual incretin receptor activation - "twincretins".
    Diabetes Obes Metab. 2016 May 10. doi: 10.1111/dom.12685.
    PubMed     Text format     Abstract available


  195. RODBARD HW, Seufert J, Aggarwal N, Cao A, et al
    Efficacy and Safety of Titrated Canagliflozin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sitagliptin.
    Diabetes Obes Metab. 2016 May 10. doi: 10.1111/dom.12684.
    PubMed     Text format     Abstract available


  196. FU AZ, Sheehan J
    Treatment Intensification for Patients with Type 2 Diabetes and Poor Glycemic Control.
    Diabetes Obes Metab. 2016 May 10. doi: 10.1111/dom.12683.
    PubMed     Text format     Abstract available


  197. DEFRONZO RA, Chilton R, Norton L, Clarke G, et al
    Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor.
    Diabetes Obes Metab. 2016;18:454-62.
    PubMed     Text format     Abstract available


  198. WILDING JP, Overgaard RV, Jacobsen LV, Jensen CB, et al
    Exposure-response analyses of liraglutide 3.0 mg for weight management.
    Diabetes Obes Metab. 2016;18:491-9.
    PubMed     Text format     Abstract available


  199. MIKKELSEN KH, Allin KH, Knop FK
    Effect of antibiotics on gut microbiota, glucose metabolism and body weight regulation: a review of the literature.
    Diabetes Obes Metab. 2016;18:444-53.
    PubMed     Text format     Abstract available


  200. HODGE RJ, Nunez DJ
    Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype?
    Diabetes Obes Metab. 2016;18:439-43.
    PubMed     Text format     Abstract available


  201. FREUDE S, Heise T, Woerle HJ, Jungnik A, et al
    Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11beta-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11beta-HSD1 inhibition after acute and multiple administrations over 2 weeks.
    Diabetes Obes Metab. 2016;18:483-90.
    PubMed     Text format     Abstract available


    January 2016
  202. WILKIN T, Greene S, McCrimmon R
    Testing the accelerator hypothesis: a new approach to type 1 diabetes prevention (adAPT 1).
    Diabetes Obes Metab. 2016;18:3-5.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: